Annual CFF
$5.75 M
+$5.65 M+5218.21%
December 31, 2023
Summary
- As of February 7, 2025, BGLC annual cash flow from financing activities is $5.75 million, with the most recent change of +$5.65 million (+5218.21%) on December 31, 2023.
- During the last 3 years, BGLC annual CFF has risen by +$5.76 million (+117534.69%).
- BGLC annual CFF is now at all-time high.
Performance
BGLC Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$199.40 K
-$373.00 K-214.86%
September 30, 2024
Summary
- As of February 7, 2025, BGLC quarterly cash flow from financing activities is -$199.40 thousand, with the most recent change of -$373.00 thousand (-214.86%) on September 30, 2024.
- Over the past year, BGLC quarterly CFF has dropped by -$373.00 thousand (-214.86%).
- BGLC quarterly CFF is now -103.47% below its all-time high of $5.75 million, reached on September 30, 2023.
Performance
BGLC Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$9500.00
-$5.95 M-99.84%
September 30, 2024
Summary
- As of February 7, 2025, BGLC TTM cash flow from financing activities is $9500.00, with the most recent change of -$5.95 million (-99.84%) on September 30, 2024.
- Over the past year, BGLC TTM CFF has dropped by -$5.95 million (-99.84%).
- BGLC TTM CFF is now -99.84% below its all-time high of $5.96 million, reached on June 30, 2024.
Performance
BGLC TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
BGLC Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5218.2% | -214.9% | -99.8% |
| 3 y3 years | +10000.0% | -10000.0% | -91.1% |
| 5 y5 years | +674.6% | -10000.0% | -91.1% |
BGLC Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -103.5% | at low | -99.8% | +133.6% |
| 5 y | 5-year | at high | +3282.7% | -103.5% | at low | -99.8% | +105.2% |
| alltime | all time | at high | +3282.7% | -103.5% | at low | -99.8% | +105.2% |
BioNexus Gene Lab Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$199.40 K(-214.9%) | $9500.00(-99.8%) |
| Jun 2024 | - | $173.60 K(+617.4%) | $5.96 M(+3.0%) |
| Mar 2024 | - | $24.20 K(+118.0%) | $5.78 M(+0.5%) |
| Dec 2023 | $5.75 M(+5218.2%) | $11.10 K(-99.8%) | $5.75 M(+0.2%) |
| Sep 2023 | - | $5.75 M(<-9900.0%) | $5.74 M(<-9900.0%) |
| Jun 2023 | - | -$2400.00(+33.3%) | -$8200.00(-107.7%) |
| Mar 2023 | - | -$1800.00(-21.7%) | $106.40 K(-1.7%) |
| Dec 2022 | $108.20 K(-483.7%) | -$2300.00(+35.3%) | $108.20 K(+2.6%) |
| Sep 2022 | - | -$1700.00(-101.5%) | $105.50 K(+4.4%) |
| Jun 2022 | - | $112.20 K(-2344.0%) | $101.10 K(-457.2%) |
| Dec 2021 | -$28.20 K | - | - |
| Dec 2021 | - | -$5000.00(-18.0%) | -$28.30 K(+34.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$6100.00(-29.1%) | -$21.00 K(+65.4%) |
| Jun 2021 | - | -$8600.00(0.0%) | -$12.70 K(+78.9%) |
| Mar 2021 | - | -$8600.00(-473.9%) | -$7100.00(+44.9%) |
| Dec 2020 | -$4900.00(-97.3%) | $2300.00(+4.5%) | -$4900.00(-93.9%) |
| Sep 2020 | - | $2200.00(-173.3%) | -$80.70 K(-55.5%) |
| Jun 2020 | - | -$3000.00(-53.1%) | -$181.50 K(-1.1%) |
| Mar 2020 | - | -$6400.00(-91.3%) | -$183.60 K(+1.5%) |
| Dec 2019 | -$180.80 K(-124.3%) | -$73.50 K(-25.5%) | -$180.80 K(+68.5%) |
| Sep 2019 | - | -$98.60 K(+1833.3%) | -$107.30 K(+1133.3%) |
| Jun 2019 | - | -$5100.00(+41.7%) | -$8700.00(+141.7%) |
| Mar 2019 | - | -$3600.00 | -$3600.00 |
| Dec 2018 | $742.90 K | - | - |
FAQ
- What is BioNexus Gene Lab annual cash flow from financing activities?
- What is the all time high annual CFF for BioNexus Gene Lab?
- What is BioNexus Gene Lab annual CFF year-on-year change?
- What is BioNexus Gene Lab quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioNexus Gene Lab?
- What is BioNexus Gene Lab quarterly CFF year-on-year change?
- What is BioNexus Gene Lab TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioNexus Gene Lab?
- What is BioNexus Gene Lab TTM CFF year-on-year change?
What is BioNexus Gene Lab annual cash flow from financing activities?
The current annual CFF of BGLC is $5.75 M
What is the all time high annual CFF for BioNexus Gene Lab?
BioNexus Gene Lab all-time high annual cash flow from financing activities is $5.75 M
What is BioNexus Gene Lab annual CFF year-on-year change?
Over the past year, BGLC annual cash flow from financing activities has changed by +$5.65 M (+5218.21%)
What is BioNexus Gene Lab quarterly cash flow from financing activities?
The current quarterly CFF of BGLC is -$199.40 K
What is the all time high quarterly CFF for BioNexus Gene Lab?
BioNexus Gene Lab all-time high quarterly cash flow from financing activities is $5.75 M
What is BioNexus Gene Lab quarterly CFF year-on-year change?
Over the past year, BGLC quarterly cash flow from financing activities has changed by -$373.00 K (-214.86%)
What is BioNexus Gene Lab TTM cash flow from financing activities?
The current TTM CFF of BGLC is $9500.00
What is the all time high TTM CFF for BioNexus Gene Lab?
BioNexus Gene Lab all-time high TTM cash flow from financing activities is $5.96 M
What is BioNexus Gene Lab TTM CFF year-on-year change?
Over the past year, BGLC TTM cash flow from financing activities has changed by -$5.95 M (-99.84%)